PRESS RELEASE

For Immediate Release

The American Board of Pathology Announces the Appointment of Dr. Dong Chen to the Test Development and Advisory Committee for Hematopathology

TAMPA, Fla., (Jan. 7, 2020) - The American Board of Pathology (ABPath) is pleased to announce the appointment of Dong Chen, MD to the ABPath’s Test Development and Advisory Committee (TDAC) for Hematopathology for 2020. The TDACs are responsible for developing and reviewing the ABPath certification exam questions that assess and certify a physician’s education, knowledge, experience, and skills in order to provide high quality care in the pathology profession.

To be appointed to a TDAC means a physician is an established subject matter expert in their subspecialty field and is current on the latest advances in the continually evolving field of pathology and patient care. TDAC committee members develop and review examination questions for statistical performance and relevance to current practice. They contribute to the validity of examinations by determining the content and distribution of items on examinations (exam blueprints). The TDACs also advise the ABPath on issues in their subspecialty area of expertise.

Dr. Dong Chen completed the Anatomic and Clinical Pathology (APCP) residency training at the University of Wisconsin-Madison in 2006 and a subsequent Hematopathology fellowship training at Mayo Clinic, Rochester, MN in 2007. He joined a faculty position at Mayo Clinic-Rochester after his fellowship and currently is a professor of Department of Laboratory Medicine and Pathology.

Dr. Chen’s clinical practice encompasses hematopathology and coagulation. He also serves as Chairs of the Division of Hematopathology, Mayo Clinic-Rochester and the CAP Hematology Cluster and Hemostasis and Thrombosis Committee. He has more than 100 peer-reviewed publications and book chapters. His research interests are inherited platelet disorders, von Willebrand disease, and myeloid neoplasms.
“As TDAC members, these physicians play a critical role in the development of the exams and are entrusted with maintaining the integrity of the board-certified designation. The appointment to a TDAC indicates the physician is highly regarded in the field of pathology and exemplifies the utmost standards of care,” states Rebecca L. Johnson, M.D., CEO of the American Board of Pathology.

Since 1971, the ABPath has appointed test committees for each specialty area of pathology. The committee consists of ABPath trustees and other pathologists or specialty physicians who are recognized experts in their respective disciplines. There are presently 14 ABPath TDACs. They are: Anatomic Pathology, Anatomic Pathology CertLink®, Blood Banking/Transfusion Medicine, Chemical Pathology, Clinical Pathology CertLink®, Management and Informatics, Cytopathology, Dermatopathology (with appointees from the American Board of Dermatology), Forensic Pathology, Hematopathology, Medical Microbiology, Molecular Genetic Pathology (with appointees from the American Board of Medical Genetics and Genomics), Neuropathology, and Pediatric Pathology.

**About the American Board of Pathology**
The mission of the American Board of Pathology, as a member of the American Board of Medical Specialties, is to serve the public and advance the profession of pathology by setting certification standards and promoting lifelong competency of pathologists. Founded in 1936, the ABPath accomplishes this mission by establishing certification and continuing certification standards and assessing the qualifications of those seeking to obtain voluntary certification in the specialty of pathology. For more information on ABPath, visit [abpath.org](http://abpath.org) or call (813) 286-2444.

###

**Contact:**
Bonnie A. Woodworth  
Communications Director  
American Board of Pathology  
(813) 724-3707  
bwoodworth@abpath.org

[abpath.org](http://abpath.org)